FDA Grants Orphan Drug Designation to Novel Mesothelioma Treatment
The U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step toward another potential therapy option for patients. ONCOFID-P is an innovative drug conjugate already in advanced clinical development for the treatment of invasive bladder cancer. The mesothelioma designation is based on preclinical data showing high antitumor activity in laboratory and mice models. Fidia Farmaceutici, a multinational research company based in Italy, announced the latest FDA designation, which is designed to encourage the development of novel drugs, par...
Source: Asbestos and Mesothelioma News - July 28, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it. D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma. “There m...
Source: Asbestos and Mesothelioma News - July 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is ...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news
Johnson & Johnson Weighs Options for Talc Liabilities
Johnson & Johnson is considering the creation of a new subsidiary to absorb its widespread asbestos liabilities, according to reports in The Wall Street Journal and other news outlets. The J&J subsidiary would then declare Chapter 11 bankruptcy, potentially saving the multinational corporation billions of dollars. Reuters News Service also reported the subsidiary possibility, citing unnamed personal injury attorneys who learned of the option while negotiating their current claims with J&J officials. A spokesperson for Johnson & Johnson would not confirm the reports. “Johnson & J...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news
New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer. Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease ha...
Source: Asbestos and Mesothelioma News - July 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Medicare Collection Agency Sets Sights on Asbestos Trusts
A prominent Medicare services collection agency is taking aim at an estimated 60 viable asbestos trust funds, citing a failure to divulge settlement payments and deliver reimbursement to providers for health care services. Asbestos trusts are designed to compensate victims of diseases caused by exposure to asbestos, most notably malignant mesothelioma, a rare cancer with no definitive cure. MSP Recovery LLC, a leading Medicare/Medicaid recovery specialist, filed the first lawsuit last week against the J.T. Thorpe Settlement Trust, according to a report in The Wall Street Journal. J.T. Thorpe Inc. is a former indus...
Source: Asbestos and Mesothelioma News - July 20, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient
(University of Texas M. D. Anderson Cancer Center) A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news
Mesothelioma Research Grants Focus on Immunotherapy
This study will start with comparisons in tumor-bearing animals treated with immunotherapy. Future drug targets will be based on the differences that are found. The goal is to find drugs that can prevent side effects while preserving robust anti-tumor response. The post Mesothelioma Research Grants Focus on Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 12, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon early data. GPS targets the WT1 protein, which is expressed in high levels of various cancers but rarely seen in normal adult cells. The protein has been especially resistant to standard chemotherapy. The vaccine works by inducing a powerfu...
Source: Asbestos and Mesothelioma News - June 29, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Mayo Clinic Opens Novel Clinical Trial for Mesothelioma
Researchers at the much-acclaimed Mayo Clinic in Rochester, Minnesota, have opened the first clinical trial for mesothelioma patients that combines a recently approved immunotherapy treatment with targeted radiation. Potential for extending survival is there. This single-center phase I clinical trial opens June 24, and is expected to enroll at least 20 participants. It will study the safety and effectiveness of stereotactic body radiation therapy, known as SBRT, when added to the immunotherapy combination of Opdivo and Yervoy. “The reasoning behind this study is that we need to build upon the success we&rsqu...
Source: Asbestos and Mesothelioma News - June 23, 2021 Category: Environmental Health Authors: Lynette Zilio Source Type: news
Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now ...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
ONCOS-102 Vaccine Showing Impressive Results for Mesothelioma
The novel immunotherapy vaccine ONCOS-102 may become the answer for the large percentage of mesothelioma cancer patients who fail to respond to a recently approved checkpoint inhibitor combination of treatment. ONCOS-102, a genetically modified oncolytic adenovirus, showed an overall survival rate of between 21.9 and 25 months in a randomized phase II clinical trial when combined with standard chemotherapy in a first-line setting. By comparison, patients in the trial receiving only standard chemotherapy had a median survival of just 13.5 months. The vaccine is the lead product of Targovax, a small Scandinavian bio...
Source: Asbestos and Mesothelioma News - June 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Breath Test Predicts Immunotherapy Response to Mesothelioma
Researchers in the Netherlands are touting a novel breath test for mesothelioma patients to better predict response to the immunotherapy combination of nivolumab and ipilimumab that was approved recently for first-line treatment of the disease. They believe exhaled breath analysis using electronic technology – known as eNose – can differentiate between responders and nonresponders before treatment begins, saving many patients from unnecessary side effects. There currently are no biomarkers for mesothelioma that can accurately predict the effectiveness of these types of immunotherapy drugs, known as immune...
Source: Asbestos and Mesothelioma News - June 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
EPA Agrees to Address Asbestos Data-Collection Deficiencies
Under pressure from a multistate coalition, the U.S. Environmental Protection Agency has agreed to tighten its data collection process for asbestos, moving the country another step closer to banning the toxic substance. The agreement comes six months after a U.S. District Court judge in California ruled the EPA must improve its ineffective data collection on asbestos imports, and two years after attorneys general in multiple states challenged in court the EPA’s lack of more restrictive asbestos regulations. “The longtime failure of the EPA to regulate asbestos is an environmental injustice and public heal...
Source: Asbestos and Mesothelioma News - June 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU
Nivolumab plus ipilimumab showed superior overall survival versus standard-of-care chemotherapy in patients with unresectable malignant mesothelioma.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
U.S. Supreme Court Rejects J & J Appeal of $2 Billion Talc Verdict
The U.S. Supreme Court rejected a request June 1 from Johnson & Johnson to consider overturning a $2.1 billion award to 22 women who blamed the company’s asbestos-contaminated talcum powder products for causing ovarian cancer. With the Supreme Court declining to consider it, a Missouri state court ruling from 2018 that originally awarded $4.69 billion remains in place. A Missouri court of appeals reduced the award in 2020 to $2.1 billion, but also rejected a J&J effort to dismiss the jury verdict. The appeal did not involve the question of whether the products caused cancer. Johnson & Johnson wanted...
Source: Asbestos and Mesothelioma News - June 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news
MD Anderson Examines Aggressive Mesothelioma Surgery in Latest Study
A retrospective study involving two decades of pleural mesothelioma patients at the heralded University of Texas MD Anderson Cancer Center failed to demonstrate a definitive survival advantage to support regular use of extrapleural pneumonectomy surgery. The most aggressive surgery possible for this type of mesothelioma – once the surgery of choice – showed no clear benefit over a more conservative procedure. When compared to the less-aggressive, lung-sparing pleurectomy and decortication surgery, EPP had a much higher perioperative mortality rate and a shorter median survival. “In comparison, we...
Source: Asbestos and Mesothelioma News - May 25, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Faulty Gene Could Raise Vulnerability to Asbestos - Linked Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 21, 2021 Category: Cancer & Oncology Tags: Oncology, Research, News, Source Type: news
Faulty Gene Could Raise Vulnerability to Asbestos-Linked Cancer
FRIDAY, May 21, 2021 -- Mutations in a certain gene may increase a person's risk for an aggressive asbestos-related cancer called malignant mesothelioma, a new study claims. The gene is called LRRK2 and is involved in regulating responses in immune... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 21, 2021 Category: General Medicine Source Type: news
Faulty Gene Could Raise Vulnerability to Asbestos-Linked Cancer
Title: Faulty Gene Could Raise Vulnerability to Asbestos-Linked CancerCategory: Health NewsCreated: 5/21/2021 12:00:00 AMLast Editorial Review: 5/21/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 21, 2021 Category: Cancer & Oncology Source Type: news
EPA Facing More Litigation on Legacy Asbestos
The Asbestos Disease Awareness Organization delivered on an earlier notice of intent to sue by filing an official complaint against the U.S. Environmental Protection Agency over its ongoing risk evaluation of asbestos. ADAO, a leading nonprofit aimed at preventing asbestos exposure, was joined by five other organizations and several public health experts in asking the court to set a deadline for the EPA to complete its work. The lawsuit was filed May 18 in the U.S. Northern District of California Court in San Francisco. The notice of intent to sue was delivered in January. Thoracic surgeon Dr. Raja Flores of Mo...
Source: Asbestos and Mesothelioma News - May 20, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
A Look at Three Decades of Real-World Mesothelioma Statistics
Despite clinical trials that often produce inflated expectations, real-world survival rates for pleural mesothelioma have failed to advance significantly over the past three decades, according to one recent study in Canada. Celebrated treatment advances have fallen short for the average patient diagnosed with this rare cancer caused by exposure to asbestos. “This is a story about a lack of progress. What we’ve seen is kind of underwhelming,” Dr. Paul Wheatley-Price, associate professor of medicine at University of Ottawa and thoracic oncologist at The Ottawa Hospital Cancer Centre, told The Mesothel...
Source: Asbestos and Mesothelioma News - May 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Asbestos-Contaminated Talc Central to Old Spice Mesothelioma Lawsuit
Willie McNeal Jr., a Vietnam War veteran and retired school bus driver, was awarded $4.8 million by a California Superior Court jury that determined asbestos-contaminated talc led to his diagnosis of malignant pleural mesothelioma. Whittaker, Clark & Daniels, a longtime talc supplier now based in South Plainfield, New Jersey, was ordered to pay McNeal $1.8 million in compensatory damages and $3 million in punitive damages. The verdict stemmed from evidence presented that an Old Spice powder product, used almost daily by McNeal for more than 20 years, contained talc from a mine in North Carolina known to be contam...
Source: Asbestos and Mesothelioma News - May 6, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Canada Moves Toward Increased Talc Restrictions
Canada may soon become the first country to legally restrict the use of popular talc-based products, stemming from an extensive, recently completed human health assessment of the naturally occurring mineral. Health Canada, the governmental agency responsible for national health policy, issued an official advisory in April, concluding that loose talc products – such as body powder, baby powder and genital deodorants – can cause serious lung problems and ovarian cancer. The agency has proposed expanded restrictions on the use of talc in cosmetics, natural health products and nonprescription drugs that can b...
Source: Asbestos and Mesothelioma News - May 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Buried Asbestos Remains a Concern at EPA Superfund Sites
Scientists have discovered that the soil composition typically used by the U.S. Environmental Protection Agency to cap asbestos Superfund sites actually increases mobility of the toxic mineral, sending it into groundwater that could endanger people nearby. This discovery disproves the long-held belief that, once buried, asbestos waste no longer presents a serious problem. The Journal of Hazardous Materials Letters published the findings in early 2021. Researchers referenced at least 16 federal Superfund sites designated by the EPA as environmental emergencies, along with many lesser-contaminated asbestos dumping grou...
Source: Asbestos and Mesothelioma News - April 29, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Combined recognition strategy allows CAR T cells to kill solid tumors in mice and avoid side effects
(American Association for the Advancement of Science) Two teams have created a new generation of highly specific CAR T cells, which safely cleared solid tumors in mice with mesothelioma, ovarian cancer, and the deadly brain cancer glioblastoma while outlasting and outperforming conventional CAR T cell designs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 28, 2021 Category: Cancer & Oncology Source Type: news
Scientists Develop Artificial Intelligence for Mesothelioma Assessment
Scientists in Scotland have developed a prototype imaging system using artificial intelligence that has proven effective with malignant mesothelioma, potentially revolutionizing the way patients will be treated in the future. The pilot program could spark much-needed advances in diagnostics and therapeutics. “Mesothelioma is such a complex, incredibly difficult disease,” Dr. Kevin Blythe, professor of respiratory medicine at University of Glasgow and respiratory physician at Queen Elizabeth University Hospital, told The Mesothelioma Center at Asbestos.com. “This could be a very important step toward...
Source: Asbestos and Mesothelioma News - April 26, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
US asbestos sites made risky by some remediation strategies
(Stanford University) Efforts to prevent human exposure to asbestos may be mobilizing the cancer-causing mineral so that it can reach water supplies, based on new findings about how the fibers move through soil. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2021 Category: Cancer & Oncology Source Type: news
Pleural Mesothelioma Patients with 5-Year Survival Still Rare
Although no amount of asbestos exposure is considered safe, lower levels of non-occupational exposure are most often linked to long-term survival for those diagnosed with malignant pleural mesothelioma, according to a recent study. Clinical Lung Cancer published the study that compared characteristics of 43 pleural mesothelioma patients who survived at least five years with the disease to a much larger control group. Several previous mesothelioma studies have estimated that the five-year survival rate is just under 5% for pleural mesothelioma, an aggressive cancer with no definitive cure. It is caused almost exclusiv...
Source: Asbestos and Mesothelioma News - April 22, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
The Case for Abandoning ‘Corporate Responsibility’ When We Judge Company Practices
In an earlier era, green referred to grass and trees and jealous eyes. But over the past half-century, green has taken on a life of its own. The Green movement deals with the collisions and contagions of the contemporary world—how to view them, and how to cure them. The book from which this essay is excerpted, The Spirit of Green, examines a wide array of social, economic and political questions from a Green vantage point. These questions include established areas such as pollution control and global warming. But they also involve new frontiers such as Green chemistry, taxes, ethics and finance. The example that foll...
Source: TIME: Science - April 20, 2021 Category: Science Authors: William Nordhaus Tags: Uncategorized climate change feature Magazine TIME 2030 Source Type: news
Triple combination therapy shows promise against a rare deadly asbestos cancer
(University Health Network) Combining immune-boosting drugs with radiation and surgery increased the survival and anticancer immune response in mouse models of mesothelioma in preclinical research by Princess Margaret Cancer Centre researchers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2021 Category: Cancer & Oncology Source Type: news
Latest KCIC Report Finds Decline in Mesothelioma Lawsuits
The number of mesothelioma lawsuits filed in 2020 dropped significantly, while cases involving lung cancer continued to increase, according to a recent study reflecting the changing face of asbestos litigation. KCIC, a well-respected consulting firm in Washington, D.C., that manages asbestos product liabilities, released its industry report Thursday. Asbestos legal filings, covering both malignant and nonmalignant disease in the United States, dropped 11% from 2019 to 2020, from 4,137 to 3,685 cases, respectively. Most prominently, there was a 9% increase in asbestos-related lung cancer filings, but a 14% decrease...
Source: Asbestos and Mesothelioma News - April 12, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
COVID Vaccine Gives Less Protection for Some Cancer Patients
Millions of people across the United States have begun receiving their COVID-19 vaccines, and restrictions are lifting in many public spaces such as restaurants and bars. Mesothelioma patients may be looking forward to returning to life as it was before the pandemic. However, a new study reports that the COVID-19 vaccine may not sufficiently protect patients with compromised or weakened immune systems. The study results suggest that people with cancer or who are undergoing cancer treatment may still be highly vulnerable to COVID-19 even after their vaccination. Researchers published their findings earlier this m...
Source: Asbestos and Mesothelioma News - March 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
BOMBSHELL: Disposable blue face masks found to contain toxic, asbestos-like substance that destroys lungs
(Natural News) Health Canada has issued a warning about blue and gray disposable face masks, which contain an asbestos-like substance associated with “early pulmonary toxicity.” The SNN200642 masks, which are made in China and sold and distributed by a Quebec-based company called Métallifer, had been part of Canada’s public school reopening plan. Students were told... (Source: NaturalNews.com)
Source: NaturalNews.com - March 30, 2021 Category: Consumer Health News Source Type: news
AI used in battle against asbestos-linked cancer
(University of Leicester) International genomics research led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 26, 2021 Category: International Medicine & Public Health Source Type: news
Thoracic Surgeon Raja Flores Enters NYC Mayor ’s Race
Thoracic surgeon and mesothelioma specialist Dr. Raja Flores wants to continue serving others, but in a new role as the next mayor of New York City. “Yes, I’m serious about this. Very serious,” Flores told The Mesothelioma Center at Asbestos.com Tuesday after another 14-hour workday and an evening surgery at Mount Sinai. “I want to take care of this city that has taken such good care of me.” Flores, the esteemed chairman of thoracic surgery at Mount Sinai Hospital, filed his official eligibility petition last week with the New York City Board of Elections. He listed himself as an inde...
Source: Asbestos and Mesothelioma News - March 25, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
Some Mesothelioma Patients May Benefit from Second Radical Surgery
This study should elicit a call of hands for centers to share their experiences, to say either do it, or not do it,” Elsayed said. “Right now, you just don’t find a good number of centers doing that second operation.” Earlier Mesothelioma Surgery Studies This most recent report focused on three smaller studies totaling 40 patients involved in a second major surgery with a curative intent for mesothelioma. In the first group of 16 patients, there was a median survival of 20.4 months after the second surgery for those with epithelial cell type, but only 7.4 months survival for those wit...
Source: Asbestos and Mesothelioma News - March 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Durvalumab immunotherapy proceeds to phase 3 trial for malignant pleural mesothelioma
(ECOG-ACRIN Cancer Research Group) The DREAM3R phase 3 clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. DREAM3R aims to enroll 480 patients with non-epithelioid or epithelioid subtype. Patients will be randomized 2:1 to receive durvalumab immunotherapy plus 4-6 cycles of chemotherapy or chemotherapy alone. Patients in the experimental group will continue to receive durvalumab after chemotherapy until disease progression, unacceptable toxicity, or patient withdrawal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news
U.S. Asbestos Imports Increased Significantly in 2020
An estimated 300 metric tons of raw chrysotile asbestos was imported into the U.S. in 2020, almost doubling the amount from 2019, according to the recent United States Geological Survey Mineral Commodity Summaries report. The chloralkali industry accounted for 100% of the imports, all from Brazil. This industry uses the asbestos in the manufacturing of semipermeable diaphragms for making chlorine. Asbestos import numbers were the second smallest in more than 50 years and only a fraction of the all-time high of 803,000 tons reported in 1973. Also imported into the United States, but not included in the report, is a...
Source: Asbestos and Mesothelioma News - March 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
New Link Between Women with Mesothelioma and Survival Genes
Men with mesothelioma outnumber women four to one. However, numerous studies have shown that women with mesothelioma often have a survival advantage over men. Now, scientists might have a better understanding of why. Researchers have identified a gene that predicts the prognosis and treatment outcome for women with malignant pleural mesothelioma. The research took place as part of the International Mesothelioma Program at Brigham and Women’s Hospital in Boston. Dr. Assunta De Rienzo led the new study after years of research highlighting the sex-based disparity among mesothelioma patients. “The goal is ...
Source: Asbestos and Mesothelioma News - March 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Legal Fight Continues Over Asbestos Disease in Libby, Mont.
The Center for Asbestos Related Disease in Libby, Montana, dodged a potential setback recently when officials from the U.S. Department of Justice decided against joining a lawsuit alleging fraudulent medical practices. Burlington Northern Santa Fe Railway filed the original suit in 2019 against the center – known as the CARD Clinic – alleging Medicare fraud that included unnecessary screenings and misdiagnosing patients with various asbestos-related diseases. The railroad giant is facing more than a thousand asbestos-related injury claims stemming from its transportation of asbestos-laden products through its r...
Source: Asbestos and Mesothelioma News - March 5, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
NCPCR issues summons to DGCI over lack of uniform test for carcinogenic substances in J & J's baby products
Time and again the commission has made attempts to seek definite information on the standardised and validated method for analysing the presence of formaldehyde in baby shampoo and asbestos in talcum powder manufactured and marketed by Johnson& Johnson Private Limited, the summons issued by the NCPCR stated. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 4, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Preparing $3.9 Billion for Talc Settlements
Pharmaceutical giant Johnson & Johnson has set aside $3.9 billion for talc-related litigation, according to a regulatory filing this week with the Securities and Exchange Commission in Washington D.C. The company said it’s now facing more than 25,000 lawsuits related to various talc products that have allegedly caused cancers, primarily from asbestos fiber contamination. The $3.9 billion is almost double the amount that Johnson & Johnson reported being set aside for litigation expenses in its 2020 fiscal year-end results. A Missouri Court of Appeals earlier last year upheld a lower-court ruling, but reduced t...
Source: Asbestos and Mesothelioma News - February 24, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
This study also is designed to better understand the biological mechanisms affecting the immune system. The goal is to use both the cellular organization and molecular pathways to develop a test that can predict the response to the checkpoint inhibitor drugs. Upon completion, a clinical trial would follow, in which treatment would depend on the results of the individual’s test. “Within the next year or two, we’ll have a good idea of whether these components are working,” Burt said. The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center - Vital S...
Source: Asbestos and Mesothelioma News - February 23, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
Winter Storm Delays Cancer Treatment Across U.S.
Severe winter storms have affected multiple central U.S. states with power outages and water supply disruptions. State officials in Texas, Louisiana and Mississippi say restoring power to everyone could still take several days. Over the past week, problems with state infrastructure left millions of residents across Texas and Oklahoma without heat and potable water. Dr. Raja Flores, a thoracic surgeon at Mount Sinai Cancer Center in New York, says the weather has also affected cancer patients in his area. “With the storm, many services are not available,” Dr. Flores told The Mesothelioma Center at Asbestos.com. ...
Source: Asbestos and Mesothelioma News - February 22, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA. “Yes, this opens the door for us,” Dr. Magnus Jaderberg, chief medical officer of Targovax, told The Mesothelioma Center at Asbestos.com. “It validates what the FDA believes is a potentially promising...
Source: Asbestos and Mesothelioma News - February 19, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
Study seeks to identify biological markers that predict mesothelioma response to treatment
(Baylor College of Medicine) The goal of this study is to develop a clinically relevant test that would enable physicians to determine whether a patient would be most likely or less likely to respond to a form of immunotherapy before the patient gets treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news
Research Reinforces Gene Mutation Links to Mesothelioma
More than ever, Dr. Michele Carbone at the University of Hawaii Cancer Center believes early testing for genetic mutations can lead to fewer cases of malignant mesothelioma and a longer survival time for many who do contract the disease. Lives can be saved. Years can be added. “It could change the way we treat these patients,” Carbone told The Mesothelioma Center at Asbestos.com. “And, in some cases, it could prevent the cancer entirely.” Carbone is director of thoracic oncology at University of Hawaii and a world leader in identifying the role of genetics in the development of mesothelioma cancer. ...
Source: Asbestos and Mesothelioma News - February 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news